NCT06293716 - CVL237 Tablets for APDS/PASLI | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 30, 2024

Primary Completion Date

December 29, 2025

Study Completion Date

March 30, 2026

Conditions

PI3K and P110delta Hyperactivation Syndrome

Interventions

DRUG

CVL237 tablets

CVL237 tablets, tablets, specification: 0.1g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.

DRUG

CVL237 placebo tablets

CVL237 tablets, tablets, specification: 0g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.

Trial Locations (1)

Shanghai Public Health Clinical Center, Shanghai

All Listed Sponsors

lead

Convalife (Shanghai) Co., Ltd.

INDUSTRY